Acadia Pharmaceuticals Expands Portfolio with Late-Stage Development Candidate for Prader-Willi Syndrome
June 18, 2023
☀️Trending News
Acadia Pharmaceuticals ($NASDAQ:ACAD) has announced the addition of a late-stage development candidate to their portfolio. The candidate, called Pimavanserin, is intended to address the symptoms of Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that is characterized by an insatiable appetite, poor growth, cognitive disability, and behavior and mood disturbances. Acadia Pharmaceuticals is a biopharmaceutical company dedicated to helping people with central nervous system (CNS) diseases. It discovers, develops and commercializes novel medicines that address unmet medical needs in neurological and related disorders.
Through its proprietary small molecule chemistry capabilities, Acadia has created a pipeline of treatment candidates for disorders including Parkinson’s disease psychosis, Alzheimer’s disease agitation, schizophrenia and PWS. Acadia’s stock is publicly traded on NASDAQ under the symbol ACAD. This addition to their portfolio bolsters Acadia’s commitment to providing effective treatments for CNS disorders. The potential for Pimavanserin in treating PWS is promising, and hopefully the product will offer help to those affected by this difficult disorder.
Price History
Following the news, its stock opened at $24.6 and closed at $25.0, up by 1.7% from the last closing price of 24.6. The development candidate, pimavanserin, is an oral, selective serotonin inverse agonist that is designed to target the underlying biological processes associated with Prader-Willi Syndrome (PWS). The development candidate has been studied in multiple Phase 3 clinical trials, which have shown that it is safe and well-tolerated in adults and adolescent patients with PWS.
The clinical trials also showed that pimavanserin had a significant effect on behavior, mood and overall quality of life when compared to placebo. Acadia Pharmaceuticals is committed to finding treatments for rare central nervous system disorders, such as PWS. This development candidate is an important step towards this goal, and the company is hopeful that it will be approved by the FDA in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 520.23 | -145.94 | -28.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -55.64 | 134.41 | 7.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 655.3 | 281.05 | 2.3 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.4% | – | -31.6% |
| FCF Margin | ROE | ROA |
| -10.7% | -26.5% | -15.7% |
Analysis
GoodWhale has analyzed ACADIA PHARMACEUTICALS and determined it to be a medium-risk investment. This assessment was based on a holistic consideration of both the financial and business aspects of the company. GoodWhale uncovered two risk warnings within the cashflow statement and financial journal, which registered users can view. We believe these risks should be taken into account when making an investment decision. We strongly recommend that potential investors review all financial information available about ACADIA PHARMACEUTICALS in order to make an informed decision. GoodWhale is always available to provide guidance and resources to help our users make the best decisions for their investments. More…
Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
ACADIA Pharmaceuticals recently announced an important addition to their portfolio, with the late-stage development candidate for Prader-Willi Syndrome. This marks a notable growth in their pipeline, increasing potential for future returns for investors. ACADIA has established itself as a leader in developing treatments for central nervous system disorders, with a focus on Parkinson’s disease, schizophrenia, and dementia.
This new candidate in development may add additional value for shareholders, increasing the stock value of the company. Investors are therefore encouraged to watch ACADIA closely as the new candidate progresses throughout its clinical trials.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
